{"article_title": "Eli Lilly CEO Lechleiter Sees Light After a Difficult Year", "article_keywords": ["lechleiter", "eli", "sees", "toughest", "revenue", "ceo", "light", "medical", "plunged", "took", "patent", "lilly", "twomonth", "topselling", "difficult"], "article_url": "http://www.wsj.com/articles/eli-lilly-ceo-lechleiter-sees-light-after-a-difficult-year-1413750917", "article_text": "Eli Lilly & Co. is deep into what Chief Executive John C. Lechleiter calls the \u201ctoughest year\u201d in the drug maker\u2019s 138-year history. Revenue at Lilly has plunged because of generic competition that followed patent expirations for several of its top-selling drugs, including the antidepressant Cymbalta.\n\nThe 61-year-old Dr. Lechleiter, meanwhile, faced one of his own toughest years in 2013: He took a two-month medical leave to...", "article_metadata": {"article.template": "snippet", "article.created": "2014-10-19T20:35:00.000Z", "article.section": "Special", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "John Lechleiter, the drug maker\u2019s chief executive, says Eli Lilly is on the mend with the approval of three new drugs this year.", "creator": "@Loftus", "image": {"src": "https://si.wsj.net/public/resources/images/CS-AA029_LILY_L_G_20141015155807.jpg", "alt": "Eli Lilly CEO Lechleiter sees light after a difficult year", "identifier": "https://si.wsj.net/public/resources/images/CS-AA029_LILY_L_D_20141015155807.jpg"}, "title": "Lilly CEO Sees Light After a Difficult Year", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB12430173822434973597404580184323064007484&headline=Eli%20Lilly%20CEO%20Lechleiter%20sees%20light%20after%20a%20difficult%20year&weburl=http://www.wsj.com/articles/SB12430173822434973597404580184323064007484"}}, "page.site.product": "WSJ", "keywords": "eli lilly,pharmaceutical r&d,tax reform,tax write-off,Eli Lilly,LLY,John C. Lechleiter,regulation,government policy,performance,earnings,dividends,research,development,management,corporate actions,shareholder activism,corporate,industrial news,corporate governance,corporate taxation,health care policy,senior level management,interviews with corporate executives,interviews,biotechnology,pharmaceuticals,health care,life sciences,biopharmaceuticals,drugs,medication", "news_keywords": "eli lilly,pharmaceutical r&d,tax reform,tax write-off,Eli Lilly,LLY,John C. Lechleiter,regulation,government policy,performance", "article.headline": "Eli Lilly CEO Lechleiter sees light after a difficult year", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/CS-AA029_LILY_L_E_20141015155807.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/CS-AA029_LILY_L_D_20141015155807.jpg"}}, "description": "John Lechleiter, the drug maker\u2019s chief executive, says Eli Lilly is on the mend with the approval of three new drugs this year.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB12430173822434973597404580184323064007484&headline=Eli%20Lilly%20CEO%20Lechleiter%20sees%20light%20after%20a%20difficult%20year&weburl=http://www.wsj.com/articles/SB12430173822434973597404580184323064007484", "user.type": "nonsubscriber", "article.page": "Special", "page.content.format": "responsive", "article.summary": "John Lechleiter, the drug maker\u2019s chief executive, says Eli Lilly is on the mend with the approval of three new drugs this year.", "page.site": "wsj", "testkeys": "C", "article.published": "2014-10-19T20:35:00.000Z", "dj.asn": "i-f261", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "embed_count": 1, "image_count": 2, "word_count": 1063, "internal_link_count": 7}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "John Lechleiter, the drug maker\u2019s chief executive, says Eli Lilly is on the mend with the approval of three new drugs this year.", "title": "Lilly CEO Sees Light After a Difficult Year", "url": "http://www.wsj.com/articles/eli-lilly-ceo-lechleiter-sees-light-after-a-difficult-year-1413750917", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/CS-AA029_LILY_L_G_20141015155807.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Peter Loftus", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Lilly CEO Sees Light After a Difficult Year", "article.type": "Journal Reports: Leadership", "article.id": "SB12430173822434973597404580184323064007484", "user.exp": "default", "article.updated": "2014-10-19T20:35:00.000Z"}, "_id": "\"57477af46914bd0286fda396\"", "article_summary": "The 61-year-old Dr. Lechleiter, meanwhile, faced one of his own toughest years in 2013: He took a two-month medical leave to...\nEli Lilly & Co. is deep into what Chief Executive John C. Lechleiter calls the \u201ctoughest year\u201d in the drug maker\u2019s 138-year history.\nRevenue at Lilly has plunged because of generic competition that followed patent expirations for several of its top-selling drugs, including the antidepressant Cymbalta."}